## Rescue of epithelial HCO<sub>3</sub><sup>-</sup> secretion in murine intestine by apical membrane expression of the cystic fibrosis transmembrane conductance regulator mutant F508del

Fang Xiao<sup>1</sup>, Junhua Li<sup>1,2</sup>, Anurag Kumar Singh<sup>1</sup>, Brigitte Riederer<sup>1</sup>, Jiang Wang<sup>1</sup>, Ayesha Sultan<sup>1</sup>, Henry Park<sup>3</sup>, Min Goo Lee<sup>3</sup>, Georg Lamprecht<sup>4</sup>, Bob J. Scholte<sup>5</sup>, Hugo R. De Jonge<sup>6</sup> and Ursula Seidler<sup>1</sup>

Departments of 5 Cell Biology and 6 Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands

### **Key points**

- Cystic fibrosis (CF) is a lethal disease characterized by low rates of epithelial Cl<sup>-</sup> and HCO<sub>3</sub><sup>-</sup> secretion and obstruction of the airways and gastrointestinal and reproductive organs by sticky mucus. HCO<sub>3</sub><sup>-</sup> secretion has recently been demonstrated to be necessary for mucus hydration.
- The most frequent CF mutation is F508del. This mutant protein is usually degraded in the proteasome. New therapeutic strategies have been developed which deliver F508del to the plasma membrane.
- Utilizing transgenic F508del mutant and cystic fibrosis transmembrane conductance regulator (CFTR) knockout mice, apical membrane expression of F508del protein was found to be associated with enhanced stimulation of intestinal HCO<sub>3</sub><sup>-</sup> secretion.
- The predominant molecular mechanism for enhanced F508del HCO<sub>3</sub><sup>-</sup> stimulation appeared to be the activation of a Cl<sup>-</sup> recycling pathway, with Cl<sup>-</sup> exit via membrane-resident F508del protein and Cl<sup>-</sup> entry in exchange for HCO<sub>3</sub><sup>-</sup> by apical Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange. In contrast, the predominant molecular mechanism for cAMP-activated HCO<sub>3</sub><sup>-</sup> secretion in WT intestine appears to be HCO<sub>3</sub><sup>-</sup> exit via CFTR itself.

**Abstract** This study investigated whether expression of the common cystic fibrosis transmembrane conductance regulator (CFTR) mutant F508del in the apical membrane of enterocytes confers increased bicarbonate secretory capacity on the intestinal epithelium of F508del mutant mice compared to that of CFTR knockout (KO) mice. CFTR KO mice, F508del mutant mice (F508del) and wild-type (WT) littermates were bred on the FVB/N background. F508del isolated brush border membrane (BBM) contained approximately 5–10% fully glycosylated band C protein compared to WT BBM. Similarly, the forskolin (FSK)-induced, CFTR-dependent short-circuit current ( $\Delta I_{\rm sc}$ ) of F508del mucosa was approximately 5–10% of WT, whereas the HCO<sub>3</sub><sup>-</sup> secretory response ( $\Delta J_{\rm HCO_3}$ ) was almost half that of WT in both duodenum and mid-colon studied *in vitro* and *in vivo*. While WT intestine retained full FSK-induced  $\Delta J_{\rm HCO_3}$  in the absence of luminal Cl<sup>-</sup>, the markedly higher  $\Delta J_{\rm HCO_3}$  than  $\Delta I_{\rm sc}$  in F508del intestine was dependent on the presence of luminal Cl<sup>-</sup>, and was blocked by CFTR inhibitors. The Ste20-related proline–alanine-rich kinases (SPAK/OSR1), which are downstream of the with-no-lysine (K) protein kinases (WNK), were rapidly phosphorylated by FSK in WT and

<sup>&</sup>lt;sup>1</sup>Department of Gastoenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

<sup>&</sup>lt;sup>2</sup> Department of Nephrology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China

<sup>&</sup>lt;sup>3</sup>Department of Pharmacology, Yonsei University, Seoul, Korea

<sup>&</sup>lt;sup>4</sup>1st Department of Medicine, University of Tübingen, Tübingen, Germany

F508del, but significantly more slowly in CFTR KO intestine. In conclusion, the data demonstrate that low levels of F508del membrane expression in the intestine of F508del mice significantly increased FSK-induced  $HCO_3^-$  secretion mediated by  $Cl^-/HCO_3^-$  exchange. However, in WT mucosa FSK elicited strong SPAK/OSR1 phosphorylation and  $Cl^-$ -independent  $HCO_3^-$  efflux. This suggests that therapeutic strategies which deliver F508del to the apical membrane have the potential to significantly enhance epithelial  $HCO_3^-$  secretion.

(Received 27 March 2012; accepted after revision 12 July 2012; first published online 16 July 2012) **Corresponding author** U. Seidler: Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology, Carl Neuberg Strasse 1, 30625, Hannover, Germany. Email: seidler.ursula@mh-hannover.de

**Abbreviations** BBM, brush border membrane; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; DRA, down regulated in adenoma; FSK, forskolin; HRP, horseradish peroxidase; NHE3, Na $^+$ /H $^+$  exchanger isoform 3;  $R_t$ , electrical resistance; PEG, polyethylene glycol; SPAK/OSR1, Ste20-related proline–alanine-rich kinases; WNK, with no lysine (K) protein kinase.

### Introduction

Cystic fibrosis (CF) epithelia display a reduction in Cl<sup>-</sup>, HCO<sub>3</sub><sup>-</sup> and fluid secretion and an increase in salt and fluid absorption (Greger *et al.* 2001; Seidler *et al.* 2009; Quinton, 2010). The pathophysiological correlates are sticky, viscous mucoid secretions impacting ductal structures of multiple glandular organs and the intestine, which result in progressive glandular destruction, and increased susceptibility to bacterial infections in the respiratory airways (Quinton, 2010). Recent data suggest that epithelial HCO<sub>3</sub><sup>-</sup> secretion may be required for the release, as well as the rheological properties, of intestinal, airway and reproductive tract mucins (Garcia *et al.* 2009; Chen *et al.* 2010; Muchekehu & Quinton, 2010), and thus be of great pathophysiological relevance.

The molecular mechanisms of epithelial HCO<sub>3</sub><sup>-</sup> secretion are complex and involve both different anion channels and Cl-/HCO3- exchangers. Likewise, the molecular correlate for defective HCO<sub>3</sub><sup>-</sup> secretion fibrosis transmembrane conductance regulator (CFTR)-deficient or CFTR mutant epithelia is controversial, but recent data point to the involvement of various transporters in different CFTR-expressing epithelia (Steward et al. 2005; Dorwart et al. 2008; Seidler et al. 2009; Beuers et al. 2010; Quinton, 2010). While evidence has accumulated over the last two decades that the CFTR anion channel may become permeable to HCO<sub>3</sub><sup>-</sup> under certain conditions (Poulsen et al. 1994, Clarke et al. 1998, Spiegel et al. 2003; Shcheynikov et al. 2004; Ishiguro et al. 2009; Park et al. 2010), it is also clear that anion exchangers from the Slc26 family are involved in epithelial HCO<sub>3</sub><sup>-</sup> secretion (Steward et al. 2005; Tuo et al. 2006; Dorwart et al. 2008; Walker et al. 2009). A recent study suggests that the activation of the with no lysine (WNK) protein kinases 1 and 4-Ste20-related proline-alanine-rich kinases (SPAK/OSR1) signalling pathway in response to a decrease in intracellular Cl<sup>-</sup> concentration in pancreatic duct cells may result in a change of the anion selectivity of CFTR from Cl<sup>-</sup> to HCO<sub>3</sub><sup>-</sup> predominance and in an inhibition of apical Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchangers (Park *et al.* 2010). On the other hand, CFTR and members of the Slc26 family have been shown to structurally interact, at least in heterologous expression systems, with reciprocal activation of their individual transport functions (Ko *et al.* 2004). Thus, two fundamentally different potential mechanisms exist for CFTR-mediated epithelial HCO<sub>3</sub><sup>-</sup> secretion, and both may be operative in different epithelia under distinct physiological conditions.

The most frequent mutation in CF patients, the F508del mutation, is the deletion of a phenylalanine residue at position 508 of the CFTR amino acid sequence. Early studies on the biosynthesis and localization of F508del-CFTR indicated that the mutant protein is not folded correctly and, as a result, is not delivered to the plasma membrane (Cheng et al. 1990, Gregory et al. 1991; Ward & Kopito, 1994). Premature degradation of F508del-CFTR can be partially inhibited by reducing the temperature of cultured cells or isolated tissue to 26°C ('temperature rescue'), leading to increased F508del-CFTR membrane expression (Denning et al. 1992). But even when F508del-CFTR reaches the plasma membrane, it is prematurely degraded (Lukacs et al. 1993; Okiyoneda et al. 2010) and displays defective anion transport (Dalemans et al. 1991; Wang et al. 2000; Tang et al. 2009). However, novel drug treatment strategies have recently been developed that directly target the molecular defects in CF patients, including substances that partially prevent the degradation of mutant CFTR in the proteasome and result in improved membrane expression and increased Cl<sup>-</sup> transport by epithelial cells (Lukacs & Verkman, 2012).

We wondered if F508del-CFTR membrane expression might restore epithelial HCO<sub>3</sub><sup>-</sup> secretion. To address this question, we utilized the F508del-CFTR mouse on the FVB/N background, in which some F508del-CFTR protein reaches the small intestinal brush border

membrane (BBM), and a residual forskolin (FSK)-induced short-circuit current  $(I_{sc})$  is measured (French et al. 1996). We determined the amount of mature, fully glycosylated (band C) CFTR protein in the BBM of wild-type (WT) and F508del intestine, measured basal and FSK-induced HCO<sub>3</sub><sup>-</sup> secretion in the duodenum and colon of WT, F508del and CFTR KO mice in vivo and in vitro, and assessed the transport mechanism(s) involved in F508del-augmented HCO<sub>3</sub><sup>-</sup> secretion. Finally, we studied (i) whether SPAK/OSR1 phosphorylation may occur during agonist stimulation of intestinal anion secretion in vivo, (ii) if this pathway may be defective in the absence of CFTR expression, (iii) whether F508del-CFTR expression at the apical membrane restores WNK signalling, and (iv) if this pathway explains the differential dependence of CFTR-mediated epithelial HCO<sub>3</sub><sup>-</sup> secretion on luminal Cl<sup>-</sup> in different experimental systems.

### **Methods**

#### **Animals**

The CFTR KO mouse strain was originally generated in the laboratory of Martin Evans (Ratcliff et al. 1993) and the F508del-mutant strain in the laboratory of Bob Scholte (French et al. 1996). Both CFTR KO and F508del mice were congenic on the FVB/N background. Mice were bred at the animal care facility of Hannover Medical School under standard temperature and light conditions, and were allowed free access to food and water. The mice received electrolyte drinking solution containing polyethylene glycol (PEG) and high  $HCO_3^-$  (in mm: 40  $Na_2SO_4$ , 75  $NaHCO_3$ , 10 NaCl, 10 KCl, 23  $g\,l^{-1}$  PEG 4000), and a fibre-free diet (Altromin, C1013) to allow survival beyond weaning. Care was taken to match the mice not only as sex-matched littermates but also in terms of an equal number of weight-matched male and female pairs in each group of experiments. WT refers to the +/+ littermates of the respective strain. All experiments involving animals were approved by the Hannover Medical School Committee on investigations involving animals and an independent committee assembled by the local authorities (Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit).

# pH-stat titration of HCO<sub>3</sub><sup>-</sup> secretory rates in isolated duodenal and mid-colonic mucosa

Ussing chamber experiments were performed as described previously (Seidler *et al.* 1997) in the open-circuit mode, with intermittent current pulses (200  $\mu$ A every 60 s) to record the electrical resistance ( $R_t$ ), and to calculate a nominal short-circuit current ( $I_{sc}$ ). Mice were subjected to brief  $CO_2$  narcosis prior to cervical dislocation

before excising intestine for isolated mucosa preparations. The excised duodenum and mid-colon were stripped of external muscle layers and mounted in Ussing chambers (0.625 cm² aperture). Neural activity and prostaglandin generation were blocked with tetrodotoxin (1  $\mu$ M, serosal) and indomethacin (3  $\mu$ M, serosal), respectively. Transepithelial  $I_{\rm sc}$  was calculated as  $\mu$ Eq cm² tissue surface area. The serosal solution contained (in mM): 108 NaCl, 25 NaHCO<sub>3</sub>, 3 KCl, 1.3 MgSO<sub>4</sub>, 2 CaCl<sub>2</sub>, 2.25 KH<sub>2</sub>PO<sub>4</sub>, 8.9 glucose, and 10 sodium pyruvate, and was gassed with 95% O<sub>2</sub>–5% CO<sub>2</sub> (pH 7.4). The mucosal solution (154 mM NaCl or 154 mM sodium gluconate) was gassed with 100% O<sub>2</sub>.

# Surgical procedure: 'in vivo duodenal/colonic loop experiment'

Mice were anaesthetized by spontaneous inhalation of isoflurane (Forene; Abbott Germany, Wiesbaden, Germany) and experiments performed as previously described (Sjoblom et al. 2009). In brief, a catheter was placed in the left carotid artery for continuous infusion of (in mm: 200 Na<sup>+</sup>, 100 CO<sub>3</sub><sup>2-</sup>, 5 K<sup>+</sup> and 5 Cl<sup>-</sup>) at a rate of  $0.30\,\mathrm{ml}\,h^{-1}$  to correct the systemic acid–base balance in isoflurane-anaesthetized mice. After ligating the pancreatic and biliary ducts, about 1 cm of the proximal duodenum was perfused for the experiments. A small polyethylene tube (PE100; polyethylene, inner diameter 1 mm) with a distal flange was advanced to the duodenal bulb, and secured by a ligature, and another PE200 (polyethylene; inner diameter 2 mm) flanged tube was secured in the distal end of the perfused segment by ligature to allow fluid drainage. A similar procedure was performed in the colon, with the input tube 2–2.5 cm distal to the caecocolonic junction and the exit tube approximately 2 cm proximal to the anus. The isolated segments with an intact blood supply were gently flushed and then perfused (Perfusor compact; Braun) at a rate of 15 ml h<sup>-1</sup> with 154 mm NaCl. Effluents from the isolated segment were visually free of bile and blood throughout all experiments. Animals were maintained at 37°C using a heating pad controlled by a rectal thermistor probe. Mice were killed at the end of the experiment by cervical dislocation while still under anaesthesia.

# Measurement of duodenal or colonic HCO<sub>3</sub><sup>-</sup> secretion in vivo

The rate of luminal alkalinization was determined by back titration of the perfusate to pH 5.0 with 2 mm HCl by use of pH-stat equipment (PHM82 Standard pH meter, Radiometer, Copenhagen, Denmark) as described (Singh *et al.* 2008). HCO<sub>3</sub><sup>-</sup> production was determined for each 10 min period and rates of luminal alkalinization are

expressed as micromoles of base secreted per centimetre of intestine per hour ( $\mu$ mol cm<sup>-1</sup> h<sup>-1</sup>).

# Intestinal brush border membrane preparation and Western blot analysis

All processes were done at 4°C. After thoroughly rinsing with phosphate-buffered saline (PBS), intestinal segments were cut open longitudinally, the mucosa scraped with a glass slide, and mucosal scrapings suspended in 2 ml of buffer A (270 mm mannitol, 12 mm Tris, 16 mm Hepes, 1 mm EGTA, 1.006 mm CaCl<sub>2</sub>, pH 7.4,  $40 \,\mu\mathrm{g}\,\mathrm{ml}^{-1}$  phenylmethylsulfonyl fluoride (PMSF),  $20 \,\mu\mathrm{g}\,\mathrm{ml}^{-1}$  leupeptin,  $20 \,\mu\mathrm{g}\,\mathrm{ml}^{-1}$  pepstatin A,  $20 \,\mu\mathrm{g}\,\mathrm{ml}^{-1}$ antipain, 1 mm dithiothreitol (DTT), 4 mm benzamidine) and homogenized gently by thorough pottering (at least 20 up and down strokes with a rotating potter (Potter S, Braun Melsungen, Germany), 1100 U min<sup>-1</sup> rotating speed). The volume was made up to 12 ml with buffer A and the homogenate was centrifuged at 2000 g for 10 min. The supernatant was collected and 1 M MgCl<sub>2</sub> added to a final concentration of 10 mm with 15 min of mixing before centrifuging at 3000 g for 15 min. Then, the supernatant was centrifuged at 30,000 g for 30 min. The pellet was suspended in buffer B (270 mm mannitol, 12 mm Tris, 16 mm Hepes, pH 7.4, 40  $\mu$ g ml<sup>-1</sup> PMSF, 20  $\mu$ g ml<sup>-1</sup> leupeptin,  $20 \,\mu \text{g ml}^{-1}$  pepstatin A,  $20 \,\mu \text{g ml}^{-1}$  antipain, 1 mm DTT, 4 mm benzamidine) and the MgCl<sub>2</sub> precipitation and centrifugation steps repeated. The supernatant was centrifuged at 30,000 g for 30 min. The pellet was resuspended in TN buffer (50 mm Tris-Cl, 150 mm NaCl, pH 7.4,  $40 \mu \text{g ml}^{-1}$  PMSF,  $20 \mu \text{g ml}^{-1}$  leupeptin,  $20 \,\mu\mathrm{g}\,\mathrm{ml}^{-1}$  pepstatin A,  $20 \,\mu\mathrm{g}\,\mathrm{ml}^{-1}$  antipain, 1 mm DTT, 4 mm benzamidine) and homogenized using a 25G needle to produce the brush border membrane (BBM) fraction used for SDS-PAGE. One hundred micrograms of BBM was denatured in sample buffer at 65°C for 10 min and resolved on a 10% SDS-polyacrylamide gel, transferred to PVDF membrane (GE Healthcare Life Sciences). Blots were blocked with 5% skimmed milk and first incubated with rat anti-CFTR (3G11 kindly provided by the CFTR Consortium; 1:500, http://cftrfolding.org/, generated against the first nucleotide binding domain) or rabbit anti- $\beta$ -actin antibody (Abcam, Cambridge, MA, USA;1:10,000) overnight at 4°C followed by horseradish peroxidase (HRP)-conjugated anti-rat antibody (KPL; 1:5,000, KPL Inc. Gaithersburg, Maryland, USA) or anti-rabbit antibody (KPL; 1:10,000) for 1 h at room temperature. Blots were developed using ECL (GE Healthcare Life Sciences).

### Assessment of SPAK phosphorylation in vivo

*In vivo* perfusion was performed as described above. Mice in the control groups were luminally perfused with iso-

tonic saline for 40 min. The experimental groups of mice were perfused with saline for 20 min, followed by either isotonic sodium gluconate or saline containing  $10~\mu\rm M$  FSK. After killing, the perfused segment was excised, and the mucosa scraped, homogenized, lysed in SDS buffer, heated at 95°C for 5 min, centrifuged at 15,000 rpm for 15 min to remove cellular debris, and stored at  $-80^{\circ}\rm C$  until further use. Western analysis was performed as described above, using rabbit anti-SPAK (Cell Signaling Technology, Inc., Danvers, MA, USA, no. 2281; 1:500), rabbit anti- $\beta$ -actin antibody (Abcam; 1:10,000) and rabbit anti-pSPAK/anti-pOSR1 (1:5000).

### Reagents

Tetrodotoxin was purchased from Biotrend Chemicals AG (Wangen, Switzerland), forskolin from Alexis Biochemicals (Lörrach, Germany), and other reagents from Sigma-Aldrich (Deisenhofen, Germany), or the suppliers given in the text. GlyH-101 was a kind gift of Alan Verkman (University of California San Francisco).

#### **Statistics**

All results were expressed as the mean  $\pm$  SEM. ' $J_{\text{HCO}}$ , ' and 'I<sub>sc</sub>' represent the mean value of basal HCO<sub>3</sub><sup>-</sup> secretion and  $I_{sc}$ , respectively, in either luminal NaCl or sodium gluconate in the 3–5 min before the administration of FSK.  $\Delta I_{\rm HCO}$ , and  $\Delta I_{\rm sc}$  represent, for each experiment, the maximal response after the secretagogue averaged over 3–5 min minus the basal value (i.e. the net stimulated murine  $HCO_3^-$  secretion or  $I_{sc}$ ). Because the time course of stimulation may differ from one experiment to the next, and because secretory rates may decline after a maximal response, the maximal value of the averaged time courses may differ from the calculated  $\Delta J_{\text{HCO}_2}$  or the  $\Delta I_{\text{sc}}$  values in the bar graphs. Data were analysed by Student's t test for paired samples or by ANOVA with post hoc analysis for multiple comparisons. P < 0.05 was considered to denote statistical significance.

### **Results**

### Western blot analysis of CFTR protein

Western blot analysis of highly purified murine small intestinal BBM revealed that the amount of mature fully glycosylated band C protein in F508del BBM was approximately 5–10% of that found in WT BBM (Fig. 1*A*); no band C was detected in CFTR KO BBM (Fig. 1*B*). Figure 1 displays representative Western blots of pooled BBM from three mice in each group. The experiment was repeated several times with similar results. However, due to weak expression of mature fully glycosylated F508del

protein, maximal loading of the gel with protein (100  $\mu$ g) was necessary for its detection, which caused the bands for the loading controls ( $\beta$ -actin, villin) to become saturated even with very short exposure times. Precise quantification and comparison of band C between WT and F508del BBM was therefore not attempted.

Basal  $HCO_3^-$  secretion ( $J_{HCO_3^-}$ ),  $HCO_3^-$  secretory response to forskolin (FSK) ( $\Delta J_{HCO_3^-}$ ), basal  $I_{sc}$ , FSK-induced  $\Delta I_{sc}$ , and tissue resistance in F508del, CFTR KO and WT duodenal mucosa *in vitro* 

The basal  $HCO_3^-$  secretory rate  $(J_{HCO_3^-})$  was not significantly different in isolated duodenal mucosa from WT and F508del, but was reduced in CFTR KO mucosa




Figure 1. Western blot analysis of isolated brush border membranes (BBM) for CFTR expression

A, analysis of highly enriched small intestinal BBM from WT and F508del littermates, probed with an anti-CFTR antibody. The F508del BBM showed  $\sim\!7\%$  of the band C concentration seen in the WT (left). Exact quantitation was not possible because maximal loading of gels with protein (100  $\mu g$ ) was necessary to make the faint band visible; this amount of protein caused the  $\beta$ -actin band to saturate. Interestingly, there is also some band B present in the BBM. This may represent alternative trafficking of CFTR to the BBM. B, in CFTR KO mice, no band B or band C was detected. Pooled BBM from 3 different mice was used for each lane. In each lane 100  $\mu g$  protein was loaded.

(in  $\mu$ mol cm<sup>-2</sup> h<sup>-1</sup>: WT: 1.41  $\pm$  0.12, F508del: 1.17  $\pm$  0.28 and CFTR KO: 1.00  $\pm$  0.22, P < 0.05, Fig. 2A). In contrast, the FSK-stimulated HCO<sub>3</sub><sup>-</sup> secretory response ( $\Delta J_{\text{HCO}_3^-}$ ) was significantly higher in F508del duodenum than in CFTR KO duodenum, but significantly lower than that in WT mucosa (Fig. 2A and C).

Calculated basal I<sub>sc</sub> was less negative (even slightly positive) in F508del and CFTR KO duodenum compared to WT (in  $\mu$ Eq cm<sup>-2</sup>: F508del: 0.15  $\pm$  0.27 and CFTR KO:  $0.68 \pm 0.27 \text{ vs. WT: } -0.65 \pm 0.32, P < 0.05, \text{ Fig. 2}B$ ), indicating a virtual lack of CFTR-mediated anion secretion in the basal state in the former epithelia, but substantial spontaneous CFTR activity in WT mucosa, despite chemical denervation and inhibition of endogenous prostaglandin synthesis. Furthermore an FSK-induced  $I_{\rm sc}$ response ( $\Delta I_{sc}$ ) was not significantly different from zero in CFTR KO duodenum, whereas there was a small  $\Delta I_{\rm sc}$  in F508del duodenal mucosa and a much greater one in WT mucosa (Fig. 2B and D). Tissue resistance  $R_t$  was highest in CFTR KO duodenal mucosa in the basal state (Fig. 2E), whereas a transient FSK-induced increase in  $R_t$  (which has been attributed to a collapse of the lateral spaces during secretion (Gawenis et al. 2004) was observed only in WT mucosa.

Because the F508del mutant has a gating defect in addition to reduced membrane stability (Dalemans et al. 1991), we added the CFTR potentiator genistein (10  $\mu$ M) together with FSK, to isolated duodenal mucosa of F508del mutant and WT littermates (Yang et al. 2003, Yu et al. 2011). The subsequent FSK+genistein-induced  $\Delta J_{\text{HCO}}$ , was higher than the FSK-induced  $\Delta J_{\text{HCO}}$ , by an absolute rate of  $0.40 \pm 0.08 \,\mu\text{Eq cm}^{-2}$  (ns), while the FSK+genistein-induced  $\Delta J_{\text{HCO},-}$  in the WT mucosa was enhanced to a similar degree (Suppl. Fig. 1). Given the fact that the effects of genistein and FSK on F508del-induced  $\Delta I_{sc}$  were not more pronounced than on WT  $\Delta I_{sc}$ , and that genistein may act through multiple mechanisms to activate CFTR (Tuo et al. 2009, 2011), this line of experiments was not pursued further. However, the experiments show that a combination of agonists stimulate HCO<sub>3</sub><sup>-</sup> secretion in F508del intestinal mucosa even further than a maximal concentration of a cAMP agonist.

## $\Delta J_{\text{HCO}_3}^-$ , $\Delta I_{\text{sc}}$ and tissue resistance in F508del, CFTR KO and WT mid-colonic mucosa *in vitro*

The next question to address was whether a  $HCO_3^-$  secretory response to FSK was also seen in the colon of F508del mice. Murine colon displays very low  $J_{HCO_3^-}$  in the proximal segment, due to high NHE3 and low DRA (Slc26a3) BBM expression (Talbot & Lytle, 2010; Xiao *et al.* 2012), but high  $J_{HCO_3^-}$  in the mid- and distal colon (Xiao *et al.* 2012). We therefore used the mid-colon

(starting 2 cm after the caecocolonic junction and ending approximately 2 cm proximal to the anus) for our studies.

Figure 3A shows the high basal  $J_{\rm HCO_3^-}$  of mid-colonic mucosa for all three genotypes (in  $\mu$ mol cm<sup>-2</sup> h<sup>-1</sup>: WT:  $4.45\pm0.19$ , F508del:  $4.35\pm0.36$  and CFTR KO:  $3.60\pm0.40$ ) with a further significant increase after FSK application. Although the time course of  $\Delta J_{\rm HCO_3^-}$  increase after FSK was significantly slower in F508del than WT mucosa, the  $J_{\rm HCO_3^-}$  was not different 30 min after FSK addition in the F508del and WT mucosa, but was significantly lower in the CFTR KO colonic mucosa (Fig. 3A, P < 0.05). However, the relative  $\Delta J_{\rm HCO_3^-}$  response expressed as a percentage of the basal rate was not significantly different in the three genotypes (Fig. 3B).

Basal  $I_{\rm sc}$  was markedly more negative in WT compared to F508del and CFTR KO mid-colonic mucosa (in  $\mu$ Eq cm<sup>-2</sup>: WT:  $-5.20 \pm 0.73$ , F508del:  $-1.03 \pm 0.35$  and

CFTR KO:  $-1.93 \pm 0.30$ ), suggesting CFTR-mediated electrogenic anion secretion despite the presence of indomethacin and TTX (Fig. 3C, P < 0.001). FSK elicited a strong  $\Delta I_{\rm sc}$  in WT mucosa, a small  $\Delta I_{\rm sc}$  in F508del mucosa, and no response in CFTR KO mucosa (Fig. 3B and D). Thus, although we could not directly quantify the F508del CFTR mutant protein in the colonic BBM (less mucosa and fewer enrichment factors for colonic vs. small intestinal BBM prevented unequivocal detection of the mutant protein in colonic preparations), functional evidence for F508del membrane expression was obtained in the colonic mucosa of F508del mice similar to results in the small intestine.

The tissue resistance of colonic mucosa was larger than that of duodenal mucosa, and was not different between the three genotypes (Fig. 3*E*). It decreased rapidly upon FSK stimulation in the WT mucosa, consistent with the opening of an apical conductance in a relatively 'tight'




Figure 2. Basal and FSK-stimulated  $J_{HCO_3}$ –,  $I_{SC}$  and resistance ( $R_t$ ) in duodenal mucosa. Time course of  $J_{HCO_3}$ – (A),  $I_{SC}$  (B) and  $R_t$  (E) in duodenal mucosa. C and D, FSK ( $10^{-5}$  M)) -induced  $\Delta J_{HCO_3}$ – and  $\Delta I_{SC}$  in duodenal mucosa of the three different genotypes. FSK-induced  $\Delta I_{SC}$  was highly significantly different between WT and the two CF genotypes, as well as different between F508del and CFTR KO duodenum. See text for further information about basal  $I_{SC}$ . \*\*\*P < 0.001, \*\*P < 0.01, \*P < 0.05; ns, no statistical difference; P = 5–11.

epithelium, and very slowly and to an overall lesser degree in the other genotypes.

## $J_{HCO_3^-}$ and FSK-induced $\Delta J_{HCO_3^-}$ across F508del, CFTR KO and WT duodenum and colon *in vivo*

We next measured  $J_{\text{HCO}_3^-}$  in luminally perfused duodenum and mid-colon before and after FSK perfusion in anaesthetized mice. In the duodenum, basal  $J_{\text{HCO}_3^-}$  prior to FSK stimulation was significantly lower in CFTR KO compared to WT and F508del mucosa (in  $\mu$ mol cm<sup>-1</sup> h<sup>-1</sup>: WT:  $5.26 \pm 0.54$ , F508del:  $5.10 \pm 0.58$  and CFTR KO:  $3.97 \pm 0.32$ , Fig. 4A, P < 0.05), whereas WT and F508del mucosa were not statistically different. In contrast, FSK-stimulated  $\Delta J_{\text{HCO}_3^-}$  was significantly higher in F508del duodenum than in CFTR KO duodenum, but significantly lower than in WT (Fig. 4A and B).

Figure 4*C* shows the high  $J_{\text{HCO}_3}^-$  in the mid-colonic mucosa of all three genotypes *in vivo* (in  $\mu$ mol cm<sup>-1</sup> h<sup>-1</sup>: WT: 9.58  $\pm$  0.48, F508del: 8.56  $\pm$  0.90 and CFTR KO: 7.82  $\pm$  0.64), with a further significant increase after FSK application (Fig. 4*C* and *D*). Again, the FSK-induced  $\Delta J_{\text{HCO}_3}^-$  in F508del mid-colon was significantly higher than that in CFTR KO colon, but significantly lower than in WT colon.

## Effect of luminal Cl<sup>-</sup> on FSK-induced $\Delta J_{HCO_3^-}$ , $\Delta I_{sc}$ and $R_t$ in WT, F508del and CFTR KO duodenal mucosa

We next explored the potential involvement of apical  $Cl^-/HCO_3^-$  exchangers in the elevated  $HCO_3^-$  secretion by F508del duodenal mucosa. Replacement of  $Cl^-$  with gluconate in the luminal bath significantly reduced basal  $J_{HCO_3^-}$  similarly in all three genotypes (in  $\mu$ mol cm<sup>-2</sup> h<sup>-1</sup>:




Figure 3. Basal and FSK-stimulated  $J_{HCO_3}$ –,  $I_{sc}$  and resistance ( $R_t$ ) in mid-colonic mucosa Effects of FSK (10<sup>-5</sup> M) on the time course of  $J_{HCO_3}$ – (A),  $I_{sc}$  (B) and  $R_t$  (E) in isolated mid-colonic mucosa. C and D, individual secretory responses in  $\Delta J_{HCO_3}$ – and  $\Delta J_{sc}$ , for the three different genotypes. In mid-colonic mucosa, the absolute magnitude of FSK-induced  $\Delta J_{HCO_3}$ – was not significantly different between each genotype. FSK-induced  $\Delta J_{sc}$  was highly significantly different between WT and the two CF genotypes. See text for further information about basal  $I_{sc}$ . \*\*\*P < 0.001; ns, no statistical difference; D = 5–11.

WT:  $1.17 \pm 0.25$  to  $0.76 \pm 0.20$ , F508del:  $0.87 \pm 0.16$  to  $0.52 \pm 0.20$  and CFTR KO:  $0.94 \pm 0.12$  to  $0.69 \pm 0.15$ , P < 0.05) (Fig. 5A). Subsequent stimulation by FSK in the absence of luminal Cl- did not significantly reduce  $\Delta J_{\rm HCO}$  in WT mucosa compared to that in the presence of luminal  $Cl^-$  (see Figs 2C and Fig. 5C), but abolished the difference in  $\Delta J_{\text{HCO}_3}^-$  between F508del and CFTR KO mucosa (Fig. 5C). This suggests that the HCO<sub>3</sub> - secretory response in the F508del mucosa is largely mediated by luminal Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange, whereas the WT duodenum is capable of Cl<sup>-</sup>-independent HCO<sub>3</sub><sup>-</sup> secretion.


The basal Isc of CFTR KO duodenal mucosa in the presence of luminal Cl- was significantly less negative than in F508del and WT mucosa (in  $\mu$ Eq cm<sup>-2</sup>: CFTR KO:  $0.19 \pm 0.33$ , F508del:  $-0.41 \pm 0.17$  and WT:  $-0.52 \pm 0.23$ , P < 0.05) (Fig. 5*B*), but increased to similar values after the removal of luminal Cl<sup>-</sup> (in  $\mu$ Eq cm<sup>-2</sup>: WT:  $-1.89 \pm 0.38$ , F508del:  $-2.06 \pm 0.73$  and CFTR KO:  $-1.87 \pm 0.38$ ) (Fig. 5*C*), demonstrating that the increase in  $I_{sc}$  after luminal Cl<sup>-</sup> removal is not primarily due to an increased electrochemical gradient for CFTR-mediated Cl<sup>-</sup> efflux, but may be a diffusion potential elicited by the charge selectivity of tight junctions. The subsequent

FSK-induced  $\Delta I_{sc}$  did not differ significantly compared to the  $\Delta I_{sc}$  in the presence of luminal Cl<sup>-</sup> and was significantly higher in WT than the other two genotypes (Figs 2D and 5D).

Tissue resistance  $(R_t)$  increased significantly upon luminal Cl<sup>-</sup> removal to similar levels in all three genotypes, and the subsequent transient increase in  $R_t$  in response to FSK was even slightly enhanced in the WT tissue compared to  $Cl^-$  containing solutions (Figs 2E and 5E).

### Effect of luminal Cl<sup>-</sup> on FSK-induced $\Delta J_{HCO_3^-}$ , $\Delta I_{sc}$ and Rt in WT, F508del and CFTR KO colonic mucosa

In mid-colonic mucosa, the substitution of luminal Cl with gluconate resulted in a dramatic decrease in basal  $J_{\rm HCO_3^-}$  in all three genotypes, consistent with high rates of luminal alkalinization mediated by apical Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange (in  $\mu$ mol cm<sup>-2</sup> h<sup>-1</sup>: WT:  $4.00 \pm 0.28$  to  $1.61 \pm 0.16$ , F508del:  $3.90 \pm 0.22$  to  $1.34 \pm 0.16$  and CFTR KO:  $4.13 \pm 0.35$  to  $1.28 \pm 0.17$ ) (Fig. 6A). These high luminal alkalinization rates are not dependent on CFTR expression, since both  $J_{HCO_2}$  and the decrease in  $J_{HCO_3}$  after removal of luminal Cl<sup>-</sup> were



40 Time(min) Luminal NaCl

Figure 4. Basal and FSK-stimulated duodenal and mid-colonic  $HCO_3^-$  secretion ( $\Delta J_{HCO_3^-}$ ) in anaesthetized mice

Time course (A and C) and magnitude of HCO<sub>3</sub>secretory response (B and D) in luminally perfused duodenum (A and B) and mid-colon (C and D) of anaesthetized WT, F508del and CFTR KO mice. FSK-induced  $\Delta J_{\text{HCO}_2}^-$  was significantly different in luminally perfused duodenum and mid-colon between each genotype. \*P < 0.05; n = 5

identical in all three genotypes. Cl $^-$  removal did not significantly influence subsequent FSK-induced  $\Delta J_{\text{HCO}_3}^-$  responses in either WT or CFTR KO mucosa, but strongly reduced  $\Delta J_{\text{HCO}_3}^-$  in the F508del mucosa to that seen in CFTR KO mucosa (Figs 3A and C and 6A and C). This suggests that similar to duodendal mucosa, F508del expression in mid-colonic mucosa elicits an FSK-induced increase in Cl $^-$ /HCO $_3$  $^-$  exchange.

Luminal Cl $^-$  removal resulted in a strong  $\Delta I_{\rm sc}$  increase in colonic mucosa from all three genotypes (in  $\mu \rm Eq\,cm^{-2}$ : WT:  $-3.01\pm0.57$  to  $-5.27\pm0.63$ , F508del:  $-0.65\pm0.20$  to  $-2.85\pm0.46$  and CFTR KO:  $-0.78\pm0.34$  to  $-2.97\pm0.34$ , P<0.01) (Fig. 6B). Subsequent FSK-elicited  $\Delta I_{\rm sc}$  was less negative in all genotypes than in the presence of luminal Cl $^-$  (Figs 3D and 6D).

Tissue resistance ( $R_t$ ) increased significantly upon luminal Cl<sup>-</sup> removal in all three genotypes and FSK application resulted in a small decrease in  $R_t$  in all three genotypes (ns) (Fig. 6E).

## NHE3 inhibition abolished the FSK-mediated small increase in luminal alkalinisation in CFTR KO mucosa

In CFTR KO duodenal as well as mid-colonic mucosa, FSK application generated a small, but significant,  $\Delta J_{\text{HCO}_3^-}$  without any change in  $I_{\text{sc}}$ , suggesting that this  $\Delta J_{\text{HCO}_3^-}$  response is unlikely to be mediated by an anion conductance (Figs 2 and 3). Inhibition of the apical Na<sup>+</sup>/H<sup>+</sup> exchanger NHE3 increases duodenal HCO<sub>3</sub><sup>-</sup>




Figure 5. Luminal Cl $^-$  removal abolished the augmentation of FSK-induced  $\Delta J_{\text{HCO}_3}{}^-$  by F508del-CFTR membrane expression in duodenal mucosa

Replacement of Cl<sup>-</sup> in the luminal bath by gluconate caused a slight decrease in the basal  $J_{HCO_3}^-$  in each genotype (A), and reduced the  $\Delta J_{HCO_3}^-$  in the F508del mucosa to the  $\Delta J_{HCO_3}^-$  values seen in the CFTR KO mucosa (A and C). These data suggest that FSK ( $10^{-5}$  M) elicits a robust  $\Delta J_{HCO_3}^-$  independently of luminal Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange in WT mucosa, whereas the augmentation of FSK-induced  $\Delta J_{HCO_3}^-$  by F508del expression requires luminal Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange. Basal  $I_{SC}$  (B) and  $R_t$  (E) increased significantly in all three genotypes after Cl<sup>-</sup> replacement by gluconate, and the  $I_{SC}$  response to FSK (D) was not different from that seen in the presence of luminal Cl<sup>-</sup> (Fig. 2). \*\*\*P < 0.001, \*P < 0.05; ns, no statistical difference; n = 5-9.

secretion *in vivo* and *in vitro* (Clarke *et al.* 2001; Furukawa *et al.* 2004; Singh *et al.* 2010). Preincubation of duodenal and mid-colonic mucosa with 20  $\mu$ M of the NHE3 inhibitor S1611 completely abolished the FSK-induced  $\Delta J_{\text{HCO}_3^-}$  in CFTR KO mucosa, and reduced it in WT and F508del mucosa. The absolute magnitude of decrease was similar in all genotypes (Fig. 7*A* and *B*).

# Can F508del-CFTR-enhanced HCO<sub>3</sub><sup>-</sup> secretion be influenced by CFTR inhibitors?

We next tested whether  $HCO_3^-$  secretion in F508del mutant intestine is sensitive to CFTR inhibitors. Figure 7*A* and *B* displays forskolin-induced  $J_{HCO_3^-}$  in WT, F508del and CFTR KO duodenal and mid-colonic mucosa

without inhibitors (left bars), after NHE3 inhibition with 20  $\mu$ M S1611 (middle bars), and after addition of the CFTR inhibitors CFTR<sub>inh</sub>-172 and GlyH-101 to the luminal bath in the continued presence of S1611 (right bars). Any residual FSK-induced  $J_{HCO_2}$  in CFTR KO mucosa was abolished by S1611 (Fig. 7Å and B, middle bars). Moreover, any residual S1611-insensitive  $\Delta J_{\text{HCO}_2}$ in F508del duodenal, WT mid-colonic and F508del mid-colonic mucosa was abolished by the CFTR inhibitors (Fig. 7A and B, right bars). Since the CFTR inhibitors had little effect on basal  $J_{\text{HCO}_3}$  (even in colonic mucosa, where the high  $J_{\rm HCO_3}$  rates are largely Cl<sup>-</sup>/HCO<sub>3</sub> exchange mediated), these results suggest that the CFTR inhibitors act predominantly by preventing F508del-CFTR acting as a Cl<sup>-</sup> recycling pathway for Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange. To also test this hypothesis in vivo, we compared the FSK-induced





Figure 6. Luminal Cl $^-$  removal abolished the augmentation of FSK-induced  $\Delta J_{\text{HCO}_3}^-$  by F508del CFTR membrane expression in mid-colonic mucosa

Replacement of CI<sup>-</sup> in the luminal bath by gluconate caused a strong decrease in the basal  $J_{HCO_3}$ <sup>-</sup> in each genotype (A), and reduced the  $\Delta J_{HCO_3}$ <sup>-</sup> in the F508del mucosa to the  $\Delta J_{HCO_3}$ <sup>-</sup> values seen in the CFTR KO mucosa (A and C). Basal  $I_{SC}$  (B) and  $R_t$  (E) increased significantly in all three genotypes, and the  $I_{SC}$  response to FSK (D) was significantly lower in WT and F508del mucosa compared to that in the in the presence of luminal CI<sup>-</sup> (Fig. 3). \*\*P < 0.01, \*P < 0.05; ns, no statistical difference; n = 5-9.

 $\Delta J_{\rm HCO_3^-}$  in the colon of anaesthetized F508del mice in the presence of CFTR inhibitors with that seen in the CFTR KO colon (of note, S1611 cannot be used in the *in vivo* experiments). The CFTR inhibitors reduced the magnitude of FSK-induced  $\Delta J_{\rm HCO_3^-}$  in F508del colon to that seen in CFTR KO colon (Fig. 8). These data suggest that the augmented FSK-induced HCO<sub>3</sub><sup>-</sup> secretory response in F508del compared to CFTR KO intestine may be dependent on the channel activity of the mutant protein. The interpretation of these experiments is complicated by the fact that CFTR<sub>inh</sub>-172 and GlyH-101 are not completely specific for CFTR (Steward *et al.* 2011,






Figure 7. FSK-induced  $\Delta J_{\text{HCO}_3}$  is reduced by NHE3 inhibition and abolished by pharmacological inhibition of CFTR in F508del duodenal and colonic mucosa

Isolated duodenal (A) and mid-colonic (B) mucosa were preincubated with S1611 (20  $\mu$ M) (middle column) or with S1611 plus the CFTR inhibitors CFTR<sub>inh</sub>-172 (20  $\mu$ M) and GlyH-101 (10  $\mu$ M) (right column). In the duodenal mucosa, S1611 preincubation alone reduced the effect of FSK on  $\Delta J_{\rm HCO_3}{}^-$  by approximately 25–35% in WT and F508del mucosa, and completely inhibited  $\Delta J_{HCO_2}^-$  in the CFTR KO mucosa (A, middle column). The CFTR inhibitors decreased the S1611-insensitive FSK-induced  $\Delta J_{HCO_2}$  by about 40% in the WT, and abolished  $\Delta J_{HCO_2}$  in the F508del mucosa (A, right column). Qualitative similar findings were obtained in the mid-colon (B). This demonstrates that F508del-CFTR channel activity is required for the FSK-induced Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange in F508del mucosa. ns, no statistical difference; \*P < 0.05 vs. CFTR KO (duodenum or mid-colon) without inhibitors, #P < 0.01 vs. WT duodenum without inhibitors, §P < 0.01 vs. F508del duodenum without inhibitors, †P < 0.05 vs. WT mid-colon without inhibitors,  $\ddagger P < 0.05 \text{ vs.}$ F508del mid-colon without inhibitors; n = 3-5.

Caputo *et al.* 2008; Kelly *et al.* 2010), nor do they fully prevent CFTR activation in intact WT intestine (see suppl. Fig. 2, and De Boeck *et al.* 2011).

# Forskolin and luminal Cl<sup>-</sup> removal induced OSR1 and SPAK phosphorylation in intestinal mucosa *in vivo*

One puzzling finding of this study is the fact that luminal Cl<sup>-</sup> removal had no inhibitory effect on FSK-induced  $\Delta J_{\text{HCO}}$  in WT mucosa, but inhibited  $\Delta J_{\text{HCO}}$  in F508del mucosa. Because this result suggests a high HCO3permeability of CFTR in WT intestine, we investigated whether luminal Cl<sup>-</sup> removal or FSK addition activates the WNK downstream kinases OSR1 and SPAK in vivo. Western blot analysis of protein lysate from scraped duodenal mucosa after in vivo perfusion with hypotonic Cl<sup>-</sup>-free solution, performed with an antibody against the phosphorylated T-loop of OSR1 and SPAK, demonstrated time-dependent phosphorylation of OSR1 and SPAK (Fig. 9A), indicating that this signal pathway is activated in murine duodenum in vivo. We next assessed whether FSK activates SPAK/OSR1. This was indeed the case (Fig. 9B), suggesting that the lack of dependence of FSK-induced  $\Delta J_{\text{HCO}_3}^-$  on luminal Cl<sup>-</sup> in WT intestine may be explained by strong SPAK/OSR1 phosphorylation during FSK stimulation.




Figure 8. Pharmacological inhibition of CFTR abolished the augmentation of FSK-induced  $\Delta J_{\text{HCO}_3}$  by F508del CFTR membrane expression in the colon of anaesthetized mice in vivo

Luminal application of CFTR<sub>inh</sub>-172 (20  $\mu$ M) and GlyH-101 (10  $\mu$ M) reduced the FSK-induced  $\Delta J_{HCO_3}^-$  in F508del perfused mid-colon (black and shaded bars) of anaesthetized mice to the level seen in the CFTR KO colon (open bar). The FSK-induced  $\Delta J_{HCO_3}^-$  in the CFTR KO colon is due to FSK-induced NHE3 inhibition; however, a sequential application of all inhibitors, as was done in Fig. 7 in isolated mucosa, is not feasible *in vivo*. \*P< 0.05; ns, no statistical difference; n = 3–5.


Finally, we assessed whether there was a difference in SPAK/OSR1 phosphorylation in WT, F508del and CFTR KO duodenum. While both FSK and luminal Cl<sup>-</sup> free perfusion quickly increased the amount of phosphorylated OSR1 and SPAK in WT duodenum, CFTR KO mucosa displayed levels of phosphorylated SPAK/OSR1 far below those seen in WT mucosa under control conditions (Fig. 9*B*–*D*). Interestingly, a significant increase in phospho-SPAK/OSR1 was also seen in F508del duodenum in response to FSK or luminal Cl<sup>-</sup> free perfusion (Fig. 9*B*–*D*). These data suggest that the low levels of Cl<sup>-</sup> conductance provided by apical membrane expression of F508del-CFTR are sufficient to restore WNK-signalling to F508del duodenal mucosa.

### **Discussion**

In 1994, Poulsen *et al.* reported HCO<sub>3</sub><sup>-</sup> permeability of CFTR in patch-clamp experiments (Poulsen *et al.* 1994),

and similar observations were subsequently made by others (Reddy & Quinton, 2003; Tang *et al.* 2009). What about HCO<sub>3</sub><sup>-</sup> transport in CFTR mutants? Some data suggest a selective loss of the CFTR HCO<sub>3</sub><sup>-</sup> conductance in disease-causing CFTR mutants that are associated with more severe CF phenotypes (Choi *et al.* 2001, Reddy & Quinton, 2003) or idiopathic pancreatitis (Schneider & Saur, 2011). Other patch-clamp studies of heterogeneously expressed CFTR mutants associated with severe CF phenotypes found both reduced Cl<sup>-</sup> and reduced HCO<sub>3</sub><sup>-</sup> permeabilities, but no change in their relationship (Tang *et al.* 2009). The most frequent CF mutation, F508del, has not been studied in this regard. It was therefore unknown whether F508del, when expressed at the apical plasma membrane, can mediate both Cl<sup>-</sup> and HCO<sub>3</sub><sup>-</sup> secretion.

In order to answer this question, we made use of F508del mice on the FVB/N background, which express a small amount of mature fully glycosylated CFTR in the brush border membrane of the small intestine (French *et al.* 1996). We bred these mice in parallel



**Figure 9. Rescue of defective WNK signalling in F508del duodenum** *A* and *B*, SPAK/OSR1 phosphorylation was observed in response to luminal perfusion with Cl<sup>-</sup> free hypotonic solution (*A*), luminal Cl<sup>-</sup> removal and FSK stimulation in WT duodenum *in vivo* (*B*). Each lane represents total protein lysate from scraped proximal duodenum after *in vivo* luminal perfusion of one mouse with the indicated perfusate. *B*, representative blot of three different experiments. *C* and *D*, summary of three experiments in individual mice of the different genotypes under the indicated experimental conditions. Values were normalised to *β*-actin levels. There was significant stimulation of SPAK/OSR1 phosphorylation in WT and F508del, but not CFTR KO mice. The significance was calculated by ANOVA *post hoc* test. \* $P \le 0.05$  and \*\* $P \le 0.01$ ; ns, no statistical difference.

with CFTR KO mice on the same congenic FVB/N background, and found approximately 5–10% of WT band C levels in highly enriched small intestine BBM from F508del mice. Interestingly, F508del duodenum and mid-colon, the two segments that are characterized by the highest  $HCO_3^-$  secretory rates in mouse intestine, both displayed significantly higher FSK-induced  $HCO_3^-$  secretory responses compared to CFTR KO mucosa, despite this small amount of mature CFTR protein in the apical membrane, and despite a rather low FSK-induced  $\Delta I_{sc}$  response. This suggests that even low expression of mature fully glycosylated F508del CFTR mutant protein in the apical membrane enabled the intestinal epithelium to secrete substantial amounts of  $HCO_3^-$  ions.

Our next step was to obtain some insight into the molecular mechanism for this F508del-augmented HCO<sub>3</sub><sup>-</sup> secretory response. Based on the literature, three potential mechanisms are feasible: first, the activated F508del-CFTR conductance is selective for HCO<sub>3</sub><sup>-</sup> over Cl<sup>-</sup>. Such a phenomenon has recently been reported for WT CFTR in pancreatic duct cells following activation of the WNK signalling pathway by low intracellular Cl<sup>-</sup> concentrations (Park et al. 2010). We therefore studied whether FSK activated the WNK signalling pathway in murine intestine by measuring the phosphorylation of the WNK1/4 downstream kinases SPAK and OSR1. We observed a strong induction of SPAK/OSR1 phosphorylation by luminal FSK application in murine intestine in vivo (Fig. 9). FSK activated the WNK signalling pathway to a similar degree to long-term removal of luminal Cl<sup>-</sup>, which may well be the explanation for the lack of inhibition of agonist-activated HCO<sub>3</sub><sup>-</sup> secretion by luminal Cl<sup>-</sup> removal, observed in this paper as well as other studies, and in different epithelia and species (Ishiguro et al. 1996, Chan et al. 1996, Guba et al. 1996, Spiegel et al. 2003, Ishiguro et al. 2009). However, we found no significant difference between SPAK/OSR1 phosphorylation in WT and F508del intestine, while SPAK phosphorylation was significantly impaired in CFTR KO intestine. This suggests that WNK signalling, with all the resultant effects on transepithelial Cl- transport, is operative in epithelia that express F508del in their apical membranes. However, because the same strong SPAK/OSR1 phosphorylation was seen in WT intestine, the findings were not sufficient to explain the relatively strong enhancement of FSK-induced HCO<sub>3</sub><sup>-</sup> secretion in F508del compared to CFTR KO intestine, despite the small amount of membrane-resident channel protein in F508del compared with WT intestinal mucosa.

A second possible explanation is that the low amount of F508del CFTR mutant protein stimulates luminal Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> anion exchangers, either by direct molecular interaction or by providing an apical shunt (recycling) pathway for Cl<sup>-</sup>. We therefore replaced Cl<sup>-</sup> in the luminal bath with the impermeant anion gluconate. This

manoeuvre did not significantly inhibit FSK-induced  $HCO_3^-$  secretion in the WT mucosa, but reduced  $\Delta J_{HCO_3^-}$  to the level seen in the complete absence of CFTR (which was found to be due to FSK inhibition of NHE3, see Fig. 7). This feature was also observed in colonic mucosa. This suggests that FSK stimulates a robust  $Cl^-$ -independent  $HCO_3^-$  conductance in WT intestine, whereas the F508del-enhanced  $HCO_3^-$  secretion occurs predominantly via  $Cl^-/HCO_3^-$  exchange (despite robust SPAK/OSR1 phosphorylation). The critical finding of this study is, therefore, that the major  $HCO_3^-$  exit pathways appear to differ in WT and F508del murine intestine, at least when this assumption is based on results obtained by the classic manoeuvre of  $Cl^-$  removal from the luminal bath.

What may be the reason for an enhanced FSK-induced apical Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange in F508del compared to CFTR KO mucosa? There are three potential reasons for this finding. First, F508del expression, with the residual apical Cl<sup>-</sup> conductance, may result in better overall tissue integrity, including better Slc26 expression levels. Similar expression levels for Slc26a6 and Slc26a3 have previously been demonstrated in CFTR KO and WT intestine by ourselves and others (Simpson et al. 2005; Tuo et al. 2006), making it unlikely that differences would exist between F508del and CFTR KO intestine. Nevertheless, we carefully studied tissue morphology in the duodenum and colon of all three genotypes. Although fine differences in villous length and thickness, crypt depth and lamina propria cell density were seen, a blinded investigator (U.S.) was unable to classify histological specimens into the groups 'KO, F508del and WT'. This suggests that under our breeding conditions, chronic intestinal changes appear late in the life of F508del and KO mice; such mice were not studied in the present project.

A second potential explanation is that expression of CFTR, even in mutant form, may enhance the expression and/or membrane trafficking of apical anion exchangers irrespective of CFTR channel function. Such an observation has been made in pancreatic cell lines, where heterologous expression of CFTR influenced the expression and/or activity of endogenous Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchangers independent of CFTR channel function (Ignath et al. 2009). We therefore tested whether the relatively specific CFTR inhibitors CFTR<sub>inh</sub>-172 (Ma et al. 2002) and GlyH-101 (Muanprasat et al. 2004) inhibited duodenal and colonic HCO<sub>3</sub><sup>-</sup> secretion to a higher degree in F508del compared to CFTR KO mucosa. Indeed, luminal CFTR<sub>inh</sub>-172 and GlyH-101 application decreased FSK-induced HCO<sub>3</sub><sup>-</sup> secretory rates in F508del mucosa to the rates observed in CFTR KO mice. Since the effects of these agents on basal HCO<sub>3</sub><sup>-</sup> secretory rates (which are strongly dependent on apical Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange, particularly in the mid-distal colon (Xiao et al. 2012), were not significant, we assume that this inhibitory effect

may be more related to CFTR channel inhibition than to (direct) Slc26 anion exchange inhibition. However, interference with other pathways cannot be fully ruled out.

A third concept that best explains our findings is that Cl<sup>-</sup> recycling at the apical membrane, as a means to activate luminal Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange, requires CFTR channel function (Greger et al. 2001; Simpson et al. 2005; Singh et al. 2010). One may speculate that Cl<sup>-</sup> exit via CFTR, coupled to Cl<sup>-</sup> uptake in exchange for HCO<sub>3</sub><sup>-</sup> exit via an electroneutral Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchanger, results an equivalent rise in  $I_{sc}$  to that of the titrated  $HCO_3^-$  in the luminal bath. However, the apical Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchangers in the intestine may, in part, be electrogenic (Chernova et al. 2005; Lamprecht et al. 2005, 2006; Ohana et al. 2009; Yamaguchi et al. 2009; Alper et al. 2011). Other conductances are also activated by FSK (Sørensen et al. 2010), and the time courses of the  $I_{sc}$  and  $HCO_3^-$  secretory responses may be different due to technical reasons. Thus, FSK-induced  $\Delta I_{sc}$  and  $\Delta J_{HCO_3}$  need not be numerically identical for Cl<sup>-</sup> recycling to explain enhanced intestinal epithelial HCO<sub>3</sub><sup>-</sup> secretion. In addition, the activation of an apical anion conductance (i.e. membrane-resident F508del) may affect membrane potential, cell volume and pH<sub>i</sub>; these events in turn may affect apical and basolateral HCO<sub>3</sub><sup>-</sup> transporters and result in an overall increase in epithelial HCO<sub>3</sub><sup>-</sup> secretion.

What may explain the observation that the magnitude of FSK-mediated  $\Delta J_{\text{HCO}_2}$  was not significantly influenced by the absence of luminal Cl<sup>-</sup> in WT mucosa, while it was reduced to levels seen in CFTR KO intestine in F508del mucosa? Our working hypothesis was that in WT mucosa, the FSK-induced activation of apical anion efflux via CFTR may cause cell shrinkage and a decrease in  $[Cl^-]_i$  (Valverde et al. 1993; MacLeod et al. 1994; Bachmann et al. 2003; Gawenis et al. 2004), which in turn may activate the WNK signalling pathway, resulting in the phosphorylation of the downstream kinases OSR1 and SPAK (Kahle et al. 2005; Park et al. 2010), and a change of the anion selectivity of CFTR from Cl<sup>-</sup> to HCO<sub>3</sub><sup>-</sup> selectivity (Park *et al.* 2010). This would explain the Cl<sup>-</sup>-independent stimulation of  $J_{\rm HCO_3}$  in WT mucosa, which we observed. To explain the dependence of FSK-mediated  $J_{HCO_2}$  on luminal Cl<sup>-</sup> in F508del mucosa, we further speculated that differences in WNK signalling may occur between WT and F508del intestine, because we anticipated that the shrinkage and loss of [Cl<sup>-</sup>]<sub>i</sub> in F508del (and CFTR KO) epithelial cells would be insufficient to activate the WNK signalling pathway. However, this was not found to be the case for F508del mucosa, in which SPAK/OSR1 phosphorylation upon either FSK addition or luminal Cl<sup>-</sup> removal was similar to WT, whereas it was significantly attenuated in CFTR KO mucosa.

Despite substantial SPAK/OSR1 phosphorylation in F508del intestine, FSK-stimulated  ${\rm HCO_3}^-$  secretion was

nevertheless dependent on luminal Cl<sup>-</sup> and thus likely to a large part be mediated by Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange. This does not preclude a HCO<sub>3</sub><sup>-</sup> permeability of F508del itself upon WNK activation, which may have simply been too small to detect, and which may become apparent when pharmacological strategies to deliver more F508del to the membrane become available. It also suggests to us that in WT intestine, luminal Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange is inhibited by FSK, not so much because of SPAK/OSR1 phosphorylation, but by the large CFTR-mediated HCO<sub>3</sub> conductance (which is high, both because the channel is strongly expressed in the membrane and because SPAK/OSR1 is phosphorylated). High CFTR-mediated HCO<sub>3</sub><sup>-</sup> conductance would reduce the driving force for HCO<sub>3</sub><sup>-</sup> efflux via Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange. However, in F508del intestine, this CFTR-mediated HCO<sub>3</sub> conductance is low (because of the small amount of F508del-CFTR protein in the membrane, irrespective of SPAK/OSR1 phosphorylation) and may not be sufficient to result in inhibition of HCO<sub>3</sub><sup>-</sup> efflux via Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange. On the contrary, apical Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange may become activated by Cl<sup>-</sup> efflux via membrane resident F508del to provide the increased HCO<sub>3</sub><sup>-</sup> efflux. Evidence in support of this hypothesis, although not firm proof, is a rapid decrease in pH<sub>i</sub> in microdissected duodenal villi after FSK application (Y. Qin, unpublished observations).

What may be the clinical significance of this finding? Species differences have been reported in the processing and membrane expression of F508del-CFTR, with better stability in murine than human epithelial cells (Ostedgaard et al. 2007). Thus, the use of a murine F508del model provided us with an epithelium with residual F508del-CFTR membrane expression even without the use of pharmacological agents to deliver more F508del to the plasma membrane. The better survival of the F508del mice with less organ pathology and fewer obstructive episodes has already been demonstrated (French et al. 1996, Wilke et al. 2011) and it stands to reason that this might be linked to the markedly higher intestinal alkalinization rates found in this study. The transporter(s) for this F508del-augmented alkalinization are most likely not predominantly the mutated CFTR, but Slc26a3 and possibly other members of this anion exchanger gene family. If a similar situation exists in CF patients, with F508del-CFTR membrane expression in intestinal mucosa either spontaneously (van Barneveld et al. 2010) or after successful treatment with pharmacological agents (Lukacs & Verkman, 2012), knowledge about the transport properties of these anion exchangers may be important for clinicians when they treat intestinal complications of CF patients.

In summary, we have shown that expression of even small amounts of F508del-CFTR in the brush border membrane significantly enhances the forskolin-induced HCO<sub>3</sub><sup>-</sup> secretory response in both murine duodenum

and colon compared to CFTR KO mice. This secretion of  $HCO_3^-$  is dependent on luminal  $Cl^-$  in both intestinal segments and therefore likely due to  $Cl^-/HCO_3^-$  exchange. In addition, the expression of F508del-CFTR partially restores WNK signalling, which is defective in CFTR-deficient intestine. Small molecules that prevent proteasome degradation of F508del-CFTR, resulting in more mutant protein reaching the apical membrane, may therefore have the potential to significantly enhance intestinal  $HCO_3^-$  secretion, improve mucus viscosity and prevent intestinal impactions.

#### References

- Alper SL, Stewart AK, Vandorpe DH, Clark JS, Horack RZ, Simpson JE, Walker NM & Clarke LL (2011). Native and recombinant Slc26a3 (downregulated in adenoma, Dra) do not exhibit properties of 2Cl<sup>-</sup>/1HCO<sub>3</sub><sup>-</sup> exchange. *Am J Physiol Cell Physiol* **300**, C276–C286.
- Bachmann O, Rossmann H, Berger UV, Colledge WH, Ratcliff R, Evans MJ, Gregor M & Seidler U (2003). cAMP-mediated regulation of murine intestinal/pancreatic Na<sup>+</sup>/HCO<sub>3</sub><sup>-</sup> cotransporter subtype pNBC1. *Am J Physiol Gastrointest Liver Physiol* **284**, G37–45.
- Beuers U, Hohenester S, de Buy Wenniger LJ, Kremer AE, Jansen PL & Elferink RP (2010). The biliary HCO<sub>3</sub><sup>-</sup> umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. *Hepatology* **52**, 1489–1496.
- Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, Sondo E, Pfeffer U, Ravazzolo R, Zegarra-Moran O & Galietta LJ (2008). TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. *Science* **322**, 590–594.
- Chan HC, Ko WH, Zhao W, Fu WO & Wong PY (1996). Evidence for independent Cl<sup>-</sup> and HCO<sub>3</sub><sup>-</sup> secretion and involvement of an apical Na<sup>+</sup>-HCO<sub>3</sub><sup>-</sup> cotransporter in cultured rat epididymal epithelia. *Exp Physiol* **81**, 515–524.
- Chen EY, Yang N, Quinton PM & Chin WC (2010). A new role for bicarbonate in mucus formation. *Am J Physiol Lung Cell Mol Physiol* **299**, L542–549.
- Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR & Smith AE (1990). Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. *Cell* **63**, 827–834.
- Chernova MN, Jiang L, Friedman DJ, Darman RB, Lohi H, Kere J, Vandorpe DH & Alper SL (2005). Functional comparison of mouse slc26a6 anion exchanger with human SLC26A6 polypeptide variants: differences in anion selectivity, regulation, and electrogenicity. *J Biol Chem* **280**, 8564–8580.
- Choi JY, Muallem D, Kiselyov K, Lee MG, Thomas PJ & Muallem S (2001). Aberrant CFTR-dependent HCO<sub>3</sub><sup>-</sup> transport in mutations associated with cystic fibrosis. *Nature* **410**, 94–97.
- Clarke LL & Harline MC (1998). Dual role of CFTR in cAMP-stimulated HCO<sub>3</sub><sup>-</sup> secretion across murine duodenum. *Am J Physiol Gastrointest Liver Physiol* **274**, G718–G726.

- Clarke LL, Stien X & Walker NM (2001). Intestinal bicarbonate secretion in cystic fibrosis mice. *JOP* 2, 263–267.
- Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, Crystal RG, Pavirani A, Lecocq JP & Lazdunski M (1991). Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. *Nature* **354**, 526–528.
- De Boeck K, Derichs N, Fajac I, de Jonge HR, Bronsveld I, Sermet I, Vermeulen F, Sheppard DN, Cuppens H, Hug M, Melotti P, Middleton PG & Wilschanski M (2011). New clinical diagnostic procedures for cystic fibrosis in Europe. *J Cyst Fibros* **10**(Suppl 2), S53–66.
- Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE & Welsh MJ (1992). Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. *Nature* **358**, 761–764.
- Dorwart MR, Shcheynikov N, Yang D & Muallem S (2008). The solute carrier 26 family of proteins in epithelial ion transport. *Physiology (Bethesda)* **23**, 104–114.
- French PJ, van Doorninck JH, Peters RH, Verbeek E, Ameen NA, Marino CR, de Jonge HR, Bijman J & Scholte BJ (1996). A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo. *J Clin Invest* **98**, 1304–1312.
- Furukawa O, Bi LC, Guth PH, Engel E, Hirokawa M & Kaunitz JD (2004). NHE3 inhibition activates duodenal bicarbonate secretion in the rat. *Am J Physiol Gastrointest Liver Physiol* **286**, G102–109.
- Garcia MA, Yang N & Quinton PM (2009). Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. *J Clin Invest* **119**, 2613–2622.
- Gawenis LR, Boyle KT, Palmer BA, Walker NM & Clarke LL (2004). Lateral intercellular space volume as a determinant of CFTR-mediated anion secretion across small intestinal mucosa. *Am J Physiol Gastrointest Liver Physiol* **286**, G1015–1023.
- Greger R, Schreiber R, Mall M, Wissner A, Hopf A, Briel M, Bleich M, Warth R & Kunzelmann K (2001). Cystic fibrosis and CFTR. *Pflugers Arch* **443**(Suppl 1), S3–7.
- Gregory RJ, Rich DP, Cheng SH, Souza DW, Paul S, Manavalan P, Anderson MP, Welsh MJ & Smith AE (1991). Maturation and function of cystic fibrosis transmembrane conductance regulator variants bearing mutations in putative nucleotide-binding domains 1 and 2. *Mol Cell Biol* 11, 3886–3893.
- Guba M, Kuhn M, Forssmann WG, Classen M, Gregor M & Seidler U (1996). Guanylin strongly stimulates rat duodenal  $HCO_3^-$  secretion: proposed mechanism and comparison with other secretagogues. *Gastroenterology* 111, 1558–1568
- Ignath I, Hegyi P, Venglovecz V, Szekely CA, Carr G, Hasegawa M, Inoue M, Takacs T, Argent BE, Gray MA & Rakonczay Z Jr (2009). CFTR expression but not Cl<sup>-</sup> transport is involved in the stimulatory effect of bile acids on apical Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity in human pancreatic duct cells. *Pancreas* **38**, 921–929.
- Ishiguro H, Steward MC, Wilson RW & Case RM (1996) Bicarbonate secretion in interlobular ducts from guinea-pig pancreas. *J Physiol* **495**, 179–191.

- Ishiguro H, Steward MC, Naruse S, Ko SB, Goto H, Case RM, Kondo T & Yamamoto A (2009). CFTR functions as a bicarbonate channel in pancreatic duct cells. *J Gen Physiol* 133, 315–326.
- Kahle KT, Wilson FH & Lifton RP (2005). Regulation of diverse ion transport pathways by WNK4 kinase: a novel molecular switch. *Trends Endocrinol Metab* **16**, 98–103.
- Kelly M, Trudel S, Brouillard F, Bouillaud F, Colas J,
  Nguyen-Khoa T, Ollero M, Edelman A & Fritsch J (2010).
  Cystic fibrosis transmembrane regulator inhibitors
  CFTRinh-172 and GlyH-101 target mitochondrial functions, independently of chloride channel inhibition. *J Pharmacol Exp Ther* 333, 60–69.
- Ko SB, Zeng W, Dorwart MR, Luo X, Kim KH, Millen L, Goto H, Naruse S, Soyombo A, Thomas PJ & Muallem S (2004). Gating of CFTR by the STAS domain of SLC26 transporters. *Nat Cell Biol* **6**, 343–350.
- Lamprecht G, Baisch S, Schoenleber E & Gregor M (2005). Transport properties of the human intestinal anion exchanger DRA (down-regulated in adenoma) in transfected HEK293 cells. *Pflugers Arch* **449**, 479–490.
- Lamprecht G, Schaefer J, Dietz K & Gregor M (2006). Chloride and bicarbonate have similar affinities to the intestinal anion exchanger DRA (down regulated in adenoma). *Pflugers Arch* **452**, 307–315.
- Lukacs GL, Chang XB, Bear C, Kartner N, Mohamed A,
   Riordan JR & Grinstein S (1993). The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane.
   Determination of functional half-lives on transfected cells. *J Biol Chem* 268, 21592–21598.
- Lukacs GL & Verkman AS (2012). CFTR: folding, misfolding and correcting the  $\Delta$ F508 conformational defect. *Trends Mol Med* **18**, 81–91.
- Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ & Verkman AS (2002). Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. *J Clin Invest* 110, 1651–1658.
- MacLeod RJ, Lembessis P & Hamilton JR (1994). Isotonic volume reduction associated with cAMP stimulation of 36Cl efflux from jejunal crypt epithelial cells. *Am J Physiol Gastrointest Liver Physiol* **267**, G387–392.
- Muanprasat C, Sonawane ND, Salinas D, Taddei A, Galietta LJ & Verkman AS (2004). Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. *J Gen Physiol* 124, 125–137.
- Muchekehu RW & Quinton PM (2010). A new role for bicarbonate secretion in cervico-uterine mucus release. *J Physiol* **588**, 2329–2342.
- Ohana E, Yang D, Shcheynikov N & Muallem S (2009). Diverse transport modes by the solute carrier 26 family of anion transporters. *J Physiol* **587**, 2179–2185.
- Okiyoneda T, Barriere H, Bagdany M, Rabeh WM, Du K, Hohfeld J, Young JC & Lukacs GL (2010). Peripheral protein quality control removes unfolded CFTR from the plasma membrane. *Science* **329**, 805–810.

- Ostedgaard LS, Rogers CS, Dong Q, Randak CO, Vermeer DW, Rokhlina T, Karp PH & Welsh MJ (2007). Processing and function of CFTR-ΔF508 are species-dependent. *Proc Natl Acad Sci U S A* **104**, 15370–15375.
- Park HW, Nam JH, Kim JY, Namkung W, Yoon JS, Lee JS, Kim KS, Venglovecz V, Gray MA, Kim KH & Lee MG (2010). Dynamic regulation of CFTR bicarbonate permeability by [Cl<sup>-</sup>]<sub>i</sub> and its role in pancreatic bicarbonate secretion. *Gastroenterology* **139**, 620–631.
- Poulsen JH, Fischer H, Illek B & Machen TE (1994). Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator. *Proc Natl Acad Sci U S A* **91**, 5340– 5344.
- Quinton PM (2010). Role of epithelial HCO<sub>3</sub><sup>-</sup> transport in mucin secretion: lessons from cystic fibrosis. *Am J Physiol Cell Physiol* **299**, C1222–1233.
- Ratcliff R, Evans MJ, Cuthbert AW, MacVinish LJ, Foster D, Anderson JR & Colledge WH (1993). Production of a severe cystic fibrosis mutation in mice by gene targeting. *Nat Genet* **4**, 35–41.
- Reddy MM & Quinton PM (2003). Control of dynamic CFTR selectivity by glutamate and ATP in epithelial cells. *Nature* **423**, 756–760.
- Schneider G & Saur D (2011). Mesenchymal stem cells: therapeutic potential for acute pancreatitis. *Gastroenterology* **140**, 779–782.
- Seidler U, Blumenstein I, Kretz A, Viellard-Baron D, Rossmann H, Colledge WH, Evans M, Ratcliff R & Gregor M (1997). A functional CFTR protein is required for mouse intestinal cAMP-, cGMP- and Ca<sup>2+</sup>-dependent HCO<sub>3</sub><sup>-</sup> secretion. *J Physiol* **505**, 411–423.
- Seidler U, Singh A, Chen M, Cinar A, Bachmann O, Zheng W, Wang J, Yeruva S & Riederer B (2009). Knockout mouse models for intestinal electrolyte transporters and regulatory PDZ adaptors: new insights into cystic fibrosis, secretory diarrhoea and fructose-induced hypertension. *Exp Physiol* **94**, 175–179.
- Shcheynikov N, Kim KH, Kim KM, Dorwart MR, Ko SB, Goto H, Naruse S, Thomas PJ & Muallem S (2004). Dynamic control of cystic fibrosis transmembrane conductance regulator Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> selectivity by external Cl<sup>-</sup>. *J Biol Chem* **279**, 21857–21865.
- Simpson JE, Gawenis LR, Walker NM, Boyle KT & Clarke LL (2005). Chloride conductance of CFTR facilitates basal Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange in the villous epithelium of intact murine duodenum. *Am J Physiol Gastrointest Liver Physiol* **288**, G1241–1251.
- Singh AK, Riederer B, Chen M, Xiao F, Krabbenhoft A, Engelhardt R, Nylander O, Soleimani M & Seidler U (2010). The switch of intestinal Slc26 exchangers from anion absorptive to HCO<sub>3</sub><sup>-</sup> secretory mode is dependent on CFTR anion channel function. *Am J Physiol Cell Physiol* **298**, C1057–1065.
- Singh AK, Riederer B, Krabbenhöft A, Bonhagen J, Rausch B, Engelhardt R, Soleimani M & Seidler U (2009). Slc26 anion transporters involvement in acid-activated duodenal HCO<sub>3</sub><sup>-</sup> secretion. *Proc Physiol Soc* **16**, C5.

- Singh AK, Sjoblom M, Zheng W, Krabbenhoft A, Riederer B, Rausch B, Manns MP, Soleimani M & Seidler U (2008). CFTR and its key role in in vivo resting and luminal acid-induced duodenal HCO<sub>3</sub><sup>-</sup> secretion. *Acta Physiol (Oxf)* **193**, 357–365.
- Sjoblom M, Singh AK, Zheng W, Wang J, Tuo BG, Krabbenhoft A, Riederer B, Gros G & Seidler U (2009). Duodenal acidity "sensing" but not epithelial HCO<sub>3</sub><sup>-</sup> supply is critically dependent on carbonic anhydrase II expression. *Proc Natl Acad Sci U S A* **106**, 13094–13099.
- Sørensen MV, Sausbier M, Ruth P, Seidler U, Riederer B, Praetorius HA & Leipziger J (2010). Adrenaline-induced colonic K<sup>+</sup> secretion is mediated by KCa1.1 (BK) channels. *J Physiol* **588**, 1763–1777.
- Spiegel S, Phillipper M, Rossmann H, Riederer B, Gregor M & Seidler U (2003). Independence of apical Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange and anion conductance in duodenal HCO<sub>3</sub><sup>-</sup> secretion. *Am J Physiol Gastrointest Liver Physiol* **285**, G887–897.
- Stewart AK, Shmukler BE, Vandorpe DH, Reimold F, Heneghan JF, Nakakuki M, Akhavein A, Ko S, Ishiguro H & Alper SL (2011). SLC26 anion exchangers of guinea pig pancreatic duct: molecular cloning and functional characterization. *Am J Physiol Cell Physiol* **301**, C289–303.
- Steward MC, Ishiguro H & Case RM (2005). Mechanisms of bicarbonate secretion in the pancreatic duct. *Annu Rev Physiol* **67**, 377–409.
- Talbot C & Lytle C (2010). Segregation of Na/H exchanger-3 and Cl/HCO<sub>3</sub> exchanger SLC26A3 (DRA) in rodent cecum and colon. *Am J Physiol Gastrointest Liver Physiol* **299**, G358–367.
- Tang L, Fatehi M & Linsdell P (2009). Mechanism of direct bicarbonate transport by the CFTR anion channel. *J Cyst Fibros* **8**, 115–121.
- Tuo B, Riederer B, Wang Z, Colledge WH, Soleimani M & Seidler U (2006). Involvement of the anion exchanger SLC26A6 in prostaglandin E2- but not forskolin-stimulated duodenal HCO<sub>3</sub><sup>-</sup> secretion. *Gastroenterology* **130**, 349\_358
- Tuo B, Wen G, Song P, Xu J, Liu X, Seidler U & Dong H (2011). Genistein stimulates duodenal HCO<sub>3</sub><sup>-</sup> secretion through PI3K pathway in mice. *Eur J Pharmacol* **651**, 159–167.
- Tuo B, Wen G & Seidler U (2009). Differential activation of the HCO<sub>3</sub><sup>-</sup> conductance through the cystic fibrosis transmembrane conductance regulator anion channel by genistein and forskolin in murine duodenum. *Br J Pharmacol* **158**, 1313–1321.
- Valverde MA, O'Brien JA, Sepulveda FV, Ratcliff R, Evans MJ & Colledge WH (1993). Inactivation of the murine cftr gene abolishes cAMP-mediated but not Ca<sup>2+</sup>-mediated secretagogue-induced volume decrease in small-intestinal crypts. *Pflugers Arch* 425, 434–438.
- van Barneveld A, Stanke F, Tamm S, Siebert B, Brandes G, Derichs N, Ballmann M, Junge S & Tümmler B (2010). Functional analysis of F508del CFTR in native human colon. *Biochim Biophys Acta* **1802**, 1062–1069.

- Verkman AS & Galietta LJ (2009). Chloride channels as drug targets. Nat Rev Drug Discov 8, 153–171.
- Walker NM, Simpson JE, Brazill JM, Gill RK, Dudeja PK, Schweinfest CW & Clarke LL (2009). Role of down-regulated in adenoma anion exchanger in HCO<sub>3</sub><sup>-</sup> secretion across murine duodenum. *Gastroenterology* **136**, 893–901.
- Wang F, Zeltwanger S, Hu S & Hwang TC (2000). Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels. J Physiol 524, 637–648.
- Ward CL & Kopito RR (1994). Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. *J Biol Chem* **269**, 25710–25718.
- Wilke M, Buijs-Offerman RM, Aarbiou J, Colledge WH, Sheppard DN, Touqui L, Bot A, Jorna H, de Jonge HR & Scholte BJ (2011). Mouse models of cystic fibrosis: phenotypic analysis and research applications. *J Cyst Fibros* **10**(Suppl 2), S152–S171
- Xiao F, Juric M, Li J, Riederer B, Yeruva S, Kumar Singh A, Zheng L, Glage S, Kollias G, Dudeja P, Tian DA, Xu G, Zhu J, Bachmann O & Seidler U (2012). Loss of downregulated in adenoma (DRA) impairs mucosal HCO<sub>3</sub><sup>-</sup> secretion in murine ileocolonic inflammation. *Inflamm Bowel Dis* 18, 101–111.
- Yamaguchi M, Ishiguro H, Steward M, Sohma Y, Yamamoto A, Shimouchi A & Kondo T (2009). Apical Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchanger stoichiometry in the modeling of HCO<sub>3</sub><sup>-</sup> transport by pancreatic duct epithelium. *J Med Invest* **56**(Suppl), 325–328.
- Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, Lukacs GL, Taddei A, Folli C, Pedemonte N, Galietta LJ & Verkman AS (2003). Nanomolar affinity small molecule correctors of defective ΔF508-CFTR chloride channel gating. *J Biol Chem* **278**, 35079–35085.
- Yu YC, Miki H, Nakamura Y, Hanyuda A, Matsuzaki Y, Abe Y, Yasui M, Tanaka K, Hwang TC, Bompadre SG & Sohma Y (2011). Curcumin and genistein additively potentiate G551D-CFTR. *J Cyst Fibros* **10**, 243–252.

### **Author contributions**

Conception and design of the experiments: F.X., H.J. U.S.; collection, analysis and interpretation of data: F.X., J.L., A.K.S., B.R., J.W., A.S., B.J.S.; drafting the article or revising it critically for important intellectual content: F.X., H.P., M.G.L. G.L., H.J, U.S. All authors approved the final version of the manuscript. The authors have no conflict of interest to disclose.

### **Acknowledgements**

This work was supported by a financial grant from Mukoviszidose e.V., Bonn, the German Cystic Fibrosis Association, and the German Science Foundations grants SFB621-C9, and Se460/13-4 (all to U.S.) and grant 2011-0016484

from the National Research Foundation of Korea (to M.G.L.). We thank Regina Engelhardt, Brigitte Rausch, Natascha Cirpka, Silke Thiele and Denise Renner for their help with the animal breeding and genotyping, and Dr med. vet. Matthias Ottinger for help with animal management.

### **Author's present address**

J. Wang: Department of Surgery, Jinling Hospital, Nanjing University, School of Medicine, 305 East Zhongshan Road, Nanjing 210002, P.R. China.